DRK Blood Donation Service Baden-Württemberg – Hessen Starts INITIATE Study to Evaluate Pathogen-Inactivated Platelet Concentrates Treated with Cerus' INTERCEPT™ Blood System in Routine Clinical Practice

Core Viewpoint - Cerus Corporation has initiated the INITIATE study in collaboration with the German Red Cross Blood Donation Service, marking a significant step in evaluating pathogen-inactivated platelets in Germany [1] Group 1: Study Details - The INITIATE study is a prospective, multicenter, non-interventional safety study [1] - It is sponsored by the DRK Blood Donation Service Baden-Württemberg-Hessen [1] - This study is the first of its kind in Germany to assess the routine use of pathogen-inactivated platelets [1]